HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew V Schally Selected Research

JV 1-53

4/2002Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew V Schally Research Topics

Disease

190Neoplasms (Cancer)
04/2022 - 01/2002
61Prostatic Neoplasms (Prostate Cancer)
06/2021 - 02/2002
25Carcinoma (Carcinomatosis)
09/2014 - 02/2002
23Breast Neoplasms (Breast Cancer)
12/2016 - 12/2002
18Endometrial Neoplasms (Endometrial Cancer)
04/2022 - 09/2002
15Inflammation (Inflammations)
02/2022 - 09/2013
15Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 09/2002
15Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2018 - 04/2004
14Lung Neoplasms (Lung Cancer)
10/2020 - 04/2003
14Neoplasm Metastasis (Metastasis)
12/2013 - 06/2002
12Glioblastoma (Glioblastoma Multiforme)
01/2022 - 09/2004
12Triple Negative Breast Neoplasms
01/2018 - 07/2009
9Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2018 - 04/2003
9Lymphoma (Lymphomas)
01/2017 - 10/2004
9Melanoma (Melanoma, Malignant)
01/2015 - 09/2004
9Pancreatic Neoplasms (Pancreatic Cancer)
05/2013 - 01/2003
8Colorectal Neoplasms (Colorectal Cancer)
02/2022 - 02/2002
8Carcinogenesis
01/2022 - 08/2003
7Body Weight (Weight, Body)
01/2021 - 02/2002
7Myocardial Infarction
09/2017 - 02/2010
7Renal Cell Carcinoma (Grawitz Tumor)
01/2017 - 08/2005
7Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2015 - 05/2003
7Colonic Neoplasms (Colon Cancer)
11/2012 - 02/2002
6Urinary Bladder Neoplasms (Bladder Cancer)
02/2021 - 01/2011
6Adenocarcinoma
01/2017 - 10/2002
5Heart Failure
06/2022 - 12/2014
5Endometriosis
11/2017 - 04/2004
4Uveal melanoma
10/2018 - 10/2013
4Wounds and Injuries (Trauma)
01/2018 - 10/2010
4Sarcoma (Soft Tissue Sarcoma)
11/2016 - 10/2002
4Leiomyoma (Uterine Fibroids)
06/2009 - 04/2004
4Brain Neoplasms (Brain Tumor)
08/2005 - 04/2003
3Fibrosis (Cirrhosis)
06/2022 - 10/2019
3Hypoxia (Hypoxemia)
01/2020 - 02/2013
3Alzheimer Disease (Alzheimer's Disease)
01/2020 - 06/2009

Drug/Important Bio-Agent (IBA)

116Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA
06/2022 - 01/2002
69Gonadotropin-Releasing Hormone (GnRH)FDA Link
06/2021 - 02/2002
66somatotropin releasing hormone receptorIBA
06/2022 - 06/2002
54Messenger RNA (mRNA)IBA
04/2022 - 02/2002
38Proteins (Proteins, Gene)FDA Link
08/2021 - 03/2002
34AndrogensIBA
06/2021 - 02/2002
34Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
12/2020 - 02/2002
33BombesinIBA
05/2014 - 03/2002
31Doxorubicin (Adriamycin)FDA LinkGeneric
10/2018 - 02/2002
29LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
02/2021 - 02/2002
28Peptides (Polypeptides)IBA
01/2021 - 03/2002
28Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2019 - 12/2003
27Hormones (Hormone)IBA
01/2021 - 09/2002
25Gastrin-Releasing PeptideIBA
05/2014 - 03/2002
23AN 204 (AN 201)IBA
01/2011 - 02/2002
22lysine(6)-doxorubicin LHRHIBA
12/2017 - 09/2002
20Har(29)- Arg(28) Nle(27) Orn(21) His(20) Orn(12,) Abu(15) His(11) Tyr(Me)(10) Har(9) Ala(8) Fpa(5,6) Arg(2) (PhAc-Ada)(0)-Tyr(1) GHRH(1-29)NH2IBA
01/2022 - 11/2010
19LigandsIBA
04/2022 - 10/2002
17Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 08/2002
16Insulin-Like Growth Factor I (IGF-1)IBA
10/2020 - 04/2002
14Somatostatin Receptors (Somatostatin Receptor)IBA
06/2018 - 02/2002
14AN 238IBA
01/2016 - 02/2002
14AN 207IBA
01/2016 - 02/2002
14cetrorelix (Cetrotide)FDA Link
06/2013 - 08/2002
13Epidermal Growth Factor (EGF)IBA
12/2016 - 03/2002
13PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2IBA
08/2016 - 02/2007
12AN 215IBA
01/2011 - 10/2003
11ErbB Receptors (EGF Receptor)IBA
12/2016 - 10/2002
11Insulin-Like Growth Factor II (Somatomedin A)IBA
12/2008 - 08/2002
10Growth Hormone (Somatotropin)IBA
06/2022 - 08/2002
10CytokinesIBA
01/2022 - 05/2011
10N-Me-Tyr1,D-Ala2,Asn8,Arg29-NHCH3-JI-38IBA
11/2021 - 02/2014
10Estrogens (Estrogen)FDA Link
12/2016 - 03/2002
10JV 1-38IBA
08/2016 - 08/2002
10Hca(6)-Leu(13)-psi(CH2N)-Tac(14)- bombesin(6-14)IBA
10/2012 - 03/2002
8Antineoplastic Agents (Antineoplastics)IBA
01/2022 - 10/2005
8Cytotoxins (Cytolysins)IBA
01/2016 - 02/2002
7MIA-690IBA
02/2022 - 01/2014
7Peptide Receptors (Peptide Receptor)IBA
06/2017 - 09/2004
7Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
01/2013 - 04/2002
7vapreotideIBA
01/2012 - 04/2002
7RC 121IBA
08/2010 - 02/2002
7RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
11/2009 - 02/2002
6NeuropeptidesIBA
12/2020 - 01/2011
6MZ 5-156IBA
09/2012 - 07/2005
6MZ-J-7-118IBA
09/2007 - 01/2005
6Protein Isoforms (Isoforms)IBA
08/2006 - 06/2002
5Phosphotransferases (Kinase)IBA
11/2017 - 05/2011
5Testosterone (Sustanon)FDA Link
06/2013 - 07/2006
5MZ-J-7-138IBA
04/2012 - 07/2005
5Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA
10/2011 - 04/2002
4EnzymesIBA
01/2020 - 06/2005
4Cadherins (E-Cadherin)IBA
01/2018 - 02/2013
4Insulin (Novolin)FDA Link
11/2015 - 08/2011
4JI-38IBA
02/2014 - 02/2010
4Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)IBA
10/2012 - 03/2002
4Peptide Hormones (Polypeptide Hormones)IBA
01/2011 - 10/2005
4Insulin-Like PeptidesIBA
01/2008 - 11/2003
3EndotoxinsIBA
01/2021 - 12/2014
3NF-kappa B (NF-kB)IBA
10/2020 - 12/2008

Therapy/Procedure

94Therapeutics
01/2022 - 01/2002
37Drug Therapy (Chemotherapy)
12/2017 - 02/2002
13Castration
06/2021 - 02/2003
7Aftercare (After-Treatment)
01/2020 - 09/2002
4Injections
10/2009 - 02/2002